A study from the University of California, La Jolla, CA, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November 2009 issue of Nature Medicine by Prof. Thistlethwaite PA, Li X and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-basedtherapy for pulmonary arterial hypertension: KSRP inhibits the development of pulmonary arterial hypertension via up regulation of its target gene. Together, pharmacological formulations encompassing “KSRP activators” may be used to treat pulmonary arterial hypertension.
Amount: $ 500
Undisclosed information: How KSRP decreases pulmonary arterial hypertension
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based therapy for pulmonary arterial hypertension: KSRP inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 28/November/2014, 23.35, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation